- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
ACR lab ensures PET research quality
The PET core laboratory of the American College of Radiology Clinical Research Center helps ensure that PET scanners used in multicenter clinical research trials meet acceptable standards, according to research done at the University of Pennsylvania.
ACR lab ensures PET research quality
The PET core laboratory of the American College of Radiology Clinical Research Center helps ensure that PET scanners used in multicenter clinical research trials meet acceptable standards, according to research done at the University of Pennsylvania. The finding was based on a review of the PET scanner qualification program of the American College of Radiology Imaging Network and reported by the PET core laboratory team. In the past three years, ACRIN has conducted a number of clinical trials with PET imaging endpoints. Several more are scheduled to begin soon. The PET qualification program requires sites intending to participate in such multicenter trials to demonstrate that the scanner set for use in the research protocol is correctly calibrated to produce high-quality images.
Four Strategies to Address the Tipping Point in Radiology
January 17th 2025In order to flip the script on the impact of the radiology workforce shortage, radiology groups and practices need to make sound investments in technologies and leverage partnerships to mitigate gaps in coverage and maximize workflow efficiencies.
Can Generative AI Facilitate Simulated Contrast Enhancement for Prostate MRI?
January 14th 2025Deep learning synthesis of contrast-enhanced MRI from non-contrast prostate MRI sequences provided an average multiscale structural similarity index of 70 percent with actual contrast-enhanced prostate MRI in external validation testing from newly published research.
Can MRI-Based AI Enhance Risk Stratification in Prostate Cancer?
January 13th 2025Employing baseline MRI and clinical data, an emerging deep learning model was 32 percent more likely to predict the progression of low-risk prostate cancer (PCa) to clinically significant prostate cancer (csPCa), according to new research.
